» Articles » PMID: 27329677

Usability Engineering Study in the European Union of a Redesigned Follitropin Alfa Pen Injector for Infertility Treatment

Overview
Publisher Informa Healthcare
Specialty Pharmacology
Date 2016 Jun 23
PMID 27329677
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The prefilled, multidose, GONAL-f (®) (follitropin alfa) pen injector was redesigned to improve ease of use and pen functionality. This usability engineering evaluation aimed to demonstrate that the redesigned pen injector could be used by the intended users to safely and effectively deliver follitropin alfa.

Methods: Formative and summative usability engineering evaluations of the pen injector, training and instructions for use (IFU) were conducted. This included an expert review, and formative and summative evaluations involving patients with infertility and fertility nurses. For the summative evaluation, participants received training and subsequently performed tasks based on three selected hazard-related use scenarios to evaluate real-world use, including simulated injections.

Results: The formative evaluations confirmed that the pen injector was ready for summative evaluation. Task performance was high in the summative evaluation for both patients and nurses; the tasks that were observed to be most difficult to complete were priming the pen, completing an incomplete injection and completing the treatment diary. Participants rated the device as having above average usability. Most patients ranked the overall system (pen injector, device training and IFU) and its individual components to be either 'extremely easy' or 'somewhat easy' to use.

Conclusions: These usability engineering evaluations demonstrated that patients and nurses could safely and effectively use the redesigned GONAL-f pen injector, and that they also found the IFU and device training to be easy to use.

Citing Articles

A comparative, observational study evaluating dosing characteristics and ovarian response using the recombinant human follicle-stimulating hormone pen injector with small-dose dial in assisted reproductive technologies treatment in Asia: IMPROVE....

Choi B, Zhou C, Ye H, Sun Y, Zhong Y, Gong F Reprod Biol Endocrinol. 2022; 20(1):15.

PMID: 35039049 PMC: 8762890. DOI: 10.1186/s12958-021-00882-2.


Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007-2017).

Fatemi H, Bilger W, Denis D, Griesinger G, La Marca A, Longobardi S Reprod Biol Endocrinol. 2021; 19(1):68.

PMID: 33975610 PMC: 8112039. DOI: 10.1186/s12958-021-00744-x.


Formative usability evaluation of a fixed-dose pen-injector platform device.

Lange J, Nemeth T Med Devices (Auckl). 2018; 11:105-112.

PMID: 29670411 PMC: 5894723. DOI: 10.2147/MDER.S159733.


Open-Label, Randomized, Two-Way, Crossover Study Assessing the Bioequivalence of the Liquid Formulation versus the Freeze-Dried Formulation of Recombinant Human FSH and Recombinant Human LH in a Fixed 2:1 Combination (Pergoveris) in....

Bagchus W, Yalkinoglu O, Wolna P Front Endocrinol (Lausanne). 2018; 8:371.

PMID: 29375477 PMC: 5768635. DOI: 10.3389/fendo.2017.00371.